<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>EBV-encoded microRNAs (miRNAs) have been identified and their functions are being studied </plain></SENT>
<SENT sid="1" pm="."><plain>The expression pattern of these miRNAs in clinical samples of EBV-associated non-Hodgkin's <z:hpo ids='HP_0002665'>lymphomas</z:hpo> is unknown </plain></SENT>
<SENT sid="2" pm="."><plain>We analyzed five primary "endemic" pediatric Burkitt's <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>), two acquired <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo> syndrome (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>)-related type I latency <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> lines, a type III latency line, three EBV(+) primary effusion <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (PEL), and three <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-related diffuse large B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>) for expression of EBV-encoded miRNAs </plain></SENT>
<SENT sid="3" pm="."><plain>A markedly elevated expression of miRNA BHRF1-3 in type III relative to its parental type I <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> line was found </plain></SENT>
<SENT sid="4" pm="."><plain>Primary unmanipulated type I <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLs</z:e> and EBV(+) PELs expressed high levels of BART2 miRNA, whereas <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCLs</z:e> expressed both BART2 and BHRF1-3 species </plain></SENT>
<SENT sid="5" pm="."><plain>BHRF1-3 miRNA expression inversely correlated with levels of a putative cellular target, the IFN-inducible T-cell attracting chemokine CXCL-11/I-<z:chebi fb="44" ids="53498">TAC</z:chebi>, and suppression of this factor was reversed by transfection of an antisense oligo to the EBV miRNA BHRF1-3 </plain></SENT>
<SENT sid="6" pm="."><plain>EBV-encoded miRNAs are expressed in primary <z:hpo ids='HP_0002665'>lymphomas</z:hpo> classically linked to the virus and are associated with the <z:mp ids='MP_0001799'>viral</z:mp> latency status </plain></SENT>
<SENT sid="7" pm="."><plain>Targeted suppression of CXCL-11/I-<z:chebi fb="44" ids="53498">TAC</z:chebi> by a <z:mp ids='MP_0001799'>viral</z:mp>-encoded miRNA may serve as an immunomodulatory mechanism in these <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
</text></document>